Navigation Links
Nventa in Medical News

Nventa announces change in Board of Directors

...her Board positions, was a tremendous asset to the nventa Board. We will miss her and wish her continued suc...l trial in women with cervical dysplasia." About nventa Biopharmaceuticals Corporation: nventa is developing innovative therapeutics for the trea...

Nventa presents HspE7 data at international HPV conference

...eek in Beijing, China. HspE7 is being developed by nventa as a therapeutic vaccine for the treatment of dise... of action that is needed to clear the infection. nventa has previously shown that HspE7, a proprietary the... and activating cells of the immune system. About nventa Corporation: ------------------------- ...

Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.

...ies Inc. As a financier, Mr. Meekison has raised equity capital for various biotechnology companies such as StressGen Biotechnologies Corporation (now nventa Biopharmaceuticals Corporation), ID Biomedical Corp., Salix Pharmaceuticals Inc., Acorda Therapeutics Inc., Inex Pharmaceuticals Corporation, Nortran ...
Nventa in Medical Technology

Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

...vant SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today pr... Poly-ICR into future internal product candidates, nventa is pursuing the development of Poly-ICR for topica...l evolve into a revenue generating opportunity for nventa in the near future." About Poly-ICR: Poly-ICR ...

Nventa Develops Proprietary Vaccine Adjuvant

...ist SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an...s its consistency in physical-chemical properties. nventa has successfully manufactured research and develop...ccines against targeted antigens and pathogens." nventa intends to incorporate Poly-ICR into its future Co...

Nventa to Present at Bio 2008 International Convention

... SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) announce...rld. The presentation will not be webcast. About nventa Biopharmaceuticals Corporation: nventa is developing innovative therapeutics for the trea...

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

...spE7 SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an...nical responses in patients with CIN. Accordingly, nventa believes that HspE7 may successfully induce a targ...le for a significant percentage of cases of CIN. nventa is currently working with the U.S. Food and Drug A...

Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

... - SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an...linical responses in patients with CIN. Therefore, nventa believes that HspE7 may successfully treat CIN by ...ate enrollment by mid-2008." In addition to CIN, nventa is currently evaluating HspE7 as a potential treat...

Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

...it SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an...ngs will be released in the next several months. nventa is currently working with the FDA to finalize tria...n patients in CIN in mid-2008. In addition to CIN, nventa is currently evaluating HspE7 as a potential treat...

Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

... SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an...reby stimulating cellular immune system responses. nventa is developing new HspE7 for multiple indications. About nventa Corporation: ...

Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

...y - SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an... is expected shortly. At the end of each cohort, nventa is also collecting immunological data that may pro...reby stimulating cellular immune system responses. nventa is developing HspE7 + Poly-ICLC for multiple indic...

Initiation of Coverage Informational Review Issued by Scimitar Equity Research

... Scimitar Equity Research, Inc. issues a review on nventa Biopharmaceuticals Corporation (TSX: NVN) entitled... website: http://www.scimitarequity.com . About nventa Corporation: nventa is developing innovative therapeutics for the trea...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

...n cells and activating cells of the immune system. nventa is pursuing clinical development of HspE7 in combination with an adjuvant. About nventa Corporation: ------------------------- nventa is developing innovative therapeutics for the trea...
Nventa in Biological Technology

Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights

... SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) today an...her human papillomavirus (HPV) therapeutics. o nventa presented positive data from preclinical studies u...d 11 target antigens. "During the quarter, nventa announced positive clinical results for our lead c...

Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR

... M&A SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN), a compa...nt for both therapeutic and prophylactic vaccines. nventa is currently advancing Poly-ICR as a means for rev... internal development. -- Partnering Poly-ICR -- nventa is currently providing Poly-ICR through Material T...

Nventa Appoints Gordon H. Busenbark to Board of Directors

...ce - SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) announce...in corporate finance and manufacturing, will serve nventa well as we continue to advance our lead product ca...ard to collaborating with the other members of the nventa board and leveraging my industry experience to hel...

Nventa Appoints John Varian to Board of Directors

...ise - SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation (TSX: NVN) announce...and acquisitions should be extremely beneficial to nventa as it grows internally and continues its path to c...nal Conference. "I am proud to join the board at nventa Biopharmaceuticals, a truly innovative company tha...

Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results

... - SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- nventa Biopharmaceuticals Corporation announced today fin...ess specified otherwise, are in Canadian dollars. nventa reported a net loss of $12,413,000, or $0.06 per s..., which generated gross proceeds of $24,807,000. nventa also reported a net loss of $2,319,000, or $0.01 p...

Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial

...In addition to safety and tolerability assessment, nventa will also collect immunological data from these pa...and activating cells of the immune system. About nventa Corporation: ------------------------- nventa is developing innovative therapeutics for the trea...

Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results

...ess specified otherwise, are in Canadian dollars. nventa reported a net loss of $3.1 million or $0.01 per s...of $14.3 million as of September 30, 2007. RECENT nventa HIGHLIGHTS - Initiated and dosed the first coh...progress our preclinical pipeline as well." About nventa Biopharmaceuticals Corporation: -----------------...

Nventa updates progress of cervical dysplasia trial with new HspE7

...In addition to safety and tolerability assessment, nventa will also collect immunological data from these pa... and activating cells of the immune system. About nventa Corporation: ------------------------- nventa is developing innovative therapeutics for the trea...

Nventa's CEO to present at two upcoming investor conferences

...emove any extra spaces if necessary.) About nventa Biopharmaceuticals Corporation: -------------------------------------------- nventa is developing innovative therapeutics for the trea... under the symbol NVN. For more information about nventa Biopharmaceuticals Corporation and access to the B...

Nventa announces publication of HspE7 data

...ng clinical development of new HspE7 (HspE7 dosed with an adjuvant). About nventa Corporation: ------------------------- nventa is developing innovative therapeutics for the treatment of viral infections...
Other Tags
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
(Date:4/17/2014)... in many serious conditions such as heart disease, epilepsy ... drug therapies. Unfortunately, there is still much scientists do ... fresh and unexpected insight into the structure of sodium ... molecules - which are responsible for ,fine-tuning, the activity ... most recent edition of the Journal of Biological ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
(Date:4/17/2014)... forests are chock full of wild animals and plant ... of fungi are churning away in the soil, decomposing ... Despite the vital role these fungi play in ecological ... Stanford-led team of scientists has generated a genetic map ... America. The work was published this week in the ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
Other Contents